Acquisition - August 9, 2018
LEO Pharma acquires prescription dermatology unit
LEO Pharma has entered into a definitive agreement to buy Bayer’s global prescription dermatology unit, including branded topical prescription treatments for acne, fungal skin infections and rosacea, and a range of topical steroids with an annual turnover in 2017 of more than 280 million euros. The acquisition will enable LEO Pharma to expand significantly in […]
Acquisition - July 31, 2018
ProPharma acquires Xendo
ProPharma Group, a portfolio company of Linden Capital Partners, announces the acquisition of Xendo Holding B.V., which also includes Sofus Regulatory Affairs AB, based in Sweden. “We are excited to support the entire ProPharma Group organization as they continue to build out capabilities and expand their global presence to better serve their customers,” said Michael Farah, […]
Acquisition - June 14, 2018
Recipharm acquires Sanofi’s CMO business
The company expands its inhalation capabilities with GBP 45 million acquisition of Sanofi CMO business located in UK. The acquisition of Sanofi’s manufacturing centre and business located in Holmes Chapel, UK, provides Recipharm with a solid platform to take further advantage of the growing respiratory drug market, it reports. It also adds additional inhalation commercial […]
Acquisition - April 13, 2018
Alexion to acquire Wilson Therapeutics for $855 million
Alexion Pharmaceuticals has made a recommended public cash offer to the shareholders in Wilson to acquire all outstanding shares in Wilson Therapeutics by way of a tender offer, through a wholly-owned subsidiary. “The acquisition of Wilson Therapeutics is a strong strategic fit for Alexion given the overlap with our current clinical and commercial focus on […]
Acquisition - March 16, 2018
Lundbeck to acquire Prexton – a deal valued up to €905 million
The two companies have signed a definitive agreement in which Lundbeck will acquire Prexton and pay €100 million upfront plus €805 million in development and sales milestones. By acquiring Prexton, Lundbeck will obtain global rights for foliglurax, which is currently in clinical phase II testing for the symptomatic treatment of OFF-time reduction in Parkinson’s disease and dyskinesia […]
Acquisition - February 28, 2018
Moberg Pharma divests Balmex for $4.25 million
Moberg Pharma AB has entered into an agreement with Randob Labs to divest the brand Balmex for a total consideration of $4.25 million (34.6 million SEK) plus the inventory value at closing. The divestment is expected to result in a capital gain of circa $0.5 million (4.4 million SEK), enabling Moberg Pharma to further focus […]
